The Future of Glioma Imaging
Standard of care glioma imaging
can
lead to uncertain clinical
decisions1,2
Inconclusive imaging results can cause unclear diagnoses, undertreatment, overtreatment, and treatment delays1,2
With low survival rates and the need to make quick decisions, imaging is particularly important for patients with gliomas1-3
Treatment plans based on inaccurate imaging contribute to poor clinical prognoses and tumors1,2
Real-world results suggest that using 18F-FET PET in conjunction with MRIs can improve confidence in clinical decisions by4,5:
Clarifying equivocal findings4,5
Avoiding unnecessary invasive procedures5
Distinguishing treatment-related change from tumor recurrence or progression5
Although SOC imaging can yield inconclusive information, studies suggest that 18F-FET PET complements and improves MRI results1,5,6
This agent is not made commercially available or approved for gliomas. It can be made and used investigationally.
18F-FET, 18F-fluoro-ethyl-tyrosine; MRI, magnetic resonance imaging; PET, positron emission tomography; SOC, standard of care.
References: 1. Law I, Albert NL, Arbizu J, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46(3):540-557. 2. Muthukumar S, Darden J, Crowley J, Witcher M, Kiser J. A comparison of PET tracers in recurrent high-grade gliomas: a systematic review. Int J Mol Sci. 2022;24(1):408. 3. Young JS, Al-Adli N, Sibih YE, et al. Recognizing the psychological impact of a glioma diagnosis on mental and behavioral health: what neurosurgeons need to know. J Neurosurg. 2023;139(1):11-19. 4. Smith NJ, Deaton TK, Territo W, et al. Hybrid 18F-fluoroethyltyrosine PET and MRI with perfusion to distinguish disease progression from treatment-related change in malignant brain tumors: the quest to beat the toughest cases. J Nucl Med. 2023;64(7):1087-1092. 5. Brendle C, Maier C, Bender B, et al. Impact of 18F-FET PET/MRI on clinical management of brain tumor patients. J Nucl Med. 2022;63(4):522-527. 6. Rosen J, Ceccon G, Bauer EK, et al. Cost effectiveness of 18F-FET PET for early treatment response assessment in glioma patients after adjuvant [generic Temodar] chemotherapy. J Nucl Med. 2022;63(11):1677-1682.
